ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease.
The mechanisms behind secondary hyperlipidemia in patients with various chronic inflammatory diseases are not known in detail. We have recently demonstrated that ACTH exerts strong hypolipidemic effects in healthy volunteers. To test the clinical relevance of this finding, we administrated ACTH during three weeks to nine hyperlipidemic steroid-treated patients with kidney disease. Before administration of ACTH 1-24, plasma ACTH concentrations were low. Treatment with ACTH led to 20 to 50% reductions in serum concentrations of triglycerides, cholesterol, LDL cholesterol and Apo B as well as of Lp(a). HDL cholesterol and Apo A1 concentrations increased by 10 to 25%. HL activity in postheparin plasma decreased by about 40% and LPL activity, which was initially low, increased by about 140%. The effects of ACTH were similar in kidney transplant recipients and in patients with inflammatory kidney disease. Our results indicate that hyperlipidemia in steroid treated patients with kidney disease may at least partly be due to iatrogenic ACTH deficiency.
Berg
A L
AL
Department of Nephrology, University Hospital, Lund, Sweden.
Nilsson-Ehle
P
P
D000324:Adrenocorticotropic Hormone / Q000172:deficiency; D000328:Adult; D003366:Cosyntropin / Q000494:pharmacology*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007674:Kidney Diseases / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D013256:Steroids; D003366:Cosyntropin; D000324:Adrenocorticotropic Hormone